TY - JOUR
T1 - Safety and efficacy of radiotherapy treatment in elderly patients with localized prostate cancer
T2 - A retrospective analysis
AU - Fiorica, F.
AU - Berretta, M.
AU - Colosimo, C.
AU - Berretta, S.
AU - Ristagno, M.
AU - Palmucci, T.
AU - Palmucci, S.
AU - Lleshi, A.
AU - Ursino, S.
AU - Fisichella, R.
AU - Spartà, D.
AU - Stefanelli, A.
AU - Cappellani, A.
AU - Tirelli, U.
AU - Cartei, F.
PY - 2010/11
Y1 - 2010/11
N2 - The purpose of this study was to evaluate the feasibility and the activity of radiotherapy treatment in patients aged ≥75 with prostate cancer (PC). From January 2000 to December 2007, 107 consecutive patients aged ≥75 years received radiotherapy with radical intent for PC. Eighty-one patients received radiotherapy in combination with a 6 months androgen suppression therapy. Variables considered were age, stage, co-morbidities according to the adult co-morbidity evaluation index (ACE-27) and performance status (PS). The median age was 79.1 years (range 76-87). The 23.4% of patients showed no co-morbidities, while the 46.7% had mild, 23.4% moderate, and 6.5% severe co-morbidities, respectively. All patients completed the planned radiation treatment. At a median follow-up of 37.8 months, the 5-year overall survival rate was 78%. There was a better survival for patients with no or mild co-morbidities (p
AB - The purpose of this study was to evaluate the feasibility and the activity of radiotherapy treatment in patients aged ≥75 with prostate cancer (PC). From January 2000 to December 2007, 107 consecutive patients aged ≥75 years received radiotherapy with radical intent for PC. Eighty-one patients received radiotherapy in combination with a 6 months androgen suppression therapy. Variables considered were age, stage, co-morbidities according to the adult co-morbidity evaluation index (ACE-27) and performance status (PS). The median age was 79.1 years (range 76-87). The 23.4% of patients showed no co-morbidities, while the 46.7% had mild, 23.4% moderate, and 6.5% severe co-morbidities, respectively. All patients completed the planned radiation treatment. At a median follow-up of 37.8 months, the 5-year overall survival rate was 78%. There was a better survival for patients with no or mild co-morbidities (p
KW - Co-morbidities
KW - Elderly patients
KW - Prostate cancer
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=77957370750&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957370750&partnerID=8YFLogxK
U2 - 10.1016/j.archger.2009.11.019
DO - 10.1016/j.archger.2009.11.019
M3 - Article
C2 - 20044153
AN - SCOPUS:77957370750
SN - 0167-4943
VL - 51
SP - 277
EP - 282
JO - Archives of Gerontology and Geriatrics
JF - Archives of Gerontology and Geriatrics
IS - 3
ER -